KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.

Charles A Leath, Wei Deng, Loren K Mell, Debra L Richardson, Joan L Walker, Laura L Holman, Jayanthi S Lea, Sudha R Amarnath, Luis Javier Santos-Reyes, Rebecca C Arend, Jyoti Mayadev, Naresh Jegadeesh, Paul DiSilvestro, Hye Sook Chon, Sharad A Ghamande, Lei Gao, Kevin Albuquerque, Junzo P Chino, Eric Donnelly, Jonathan M Feddock, Jessica Lowenstein, Allison M Quick, Charles M Kunos, Helen MacKay, Carol Aghajanian, Bradley J Monk

Gynecol Oncol 195 122-133

PMID40101606
PMCIDPMC12009185
DOI10.1016/j.ygyno.2025.03.007
发表日期2025-03-18
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: Cisplatin-based chemoradiation (CRT) plus brachytherapy for locally advanced cervical cancer (LACC) is standard. Intrinsic overexpression of ribonucleotide reductase (RNR) may enhance DNA damage repair from CRT. We report on outcomes of adding RNR inhibitor, triapine (T), to CRT. METHODS: NRG-GY006 is an open-label randomized phase III trial. FIGO 2009 LACC (stages IB2, II, IIIB or IVA) without para-aortic nodal involvement or stages II-IV vaginal cancer were eligible. Random assignment to CRT or in combination with thrice-weekly T (CRT + T) occurred. Radiation consisted of either 3D conformal (3DCRT) or image-guided intensity modulated RT (IG-IMRT) followed by intracavitary brachytherapy. Primary endpoint was overall survival (OS). Progression-free survival (PFS) was secondary. Exploratory endpoints included complete metabolic response rate on post treatment PET/CT imaging and comparative toxicity and outcomes for 3DCRT vs. IG-IMRT. FINDINGS: Four-hundred-fifty patients were randomized including 448 eligible (224 in CRT and 224 in CRT + T). Median age was 47 (range 23-85). The majority had cervical cancer (93.3 %) with squamous histology (82 %). 52 % had FIGO stage II disease. Racial/ethnic distribution included non-Hispanic white (53.8 %), black (15.2 %) and Hispanic/Latina (22.5 %). At randomization, IG-IMRT was planned in 74.3 % and HDR brachytherapy in 98.2 %. No differences in Grade 3-5 toxicities were observed: CRT: 52 % and CRT + T: 49 %, with two G5 toxicities (cardiac arrest and acidosis) in the CRT + T arm. The median patient follow-up was 28 months (IQR 15-45). HR for death was 1.018 (95 % CI 0.634-1.635) while HR for progression was 1.021 (95 % CI 0.694-1.501). INTERPRETATION: Triapine added to CRT did not improve OS.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2 – Overall Survival (OS) by Kaplan-Meier method per randomized therapy

OS

Overall Survival

Figure 2 · Panel OS

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel OS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 – CONSORT diagram
非 KM Figure
Figure 3Figure 3 – Subgroup analyses of Progression-Free Survival (3A) and Overall Survival (3B) per treatment and tumor characteristics associated with outcomes
非 KM Figure